Class I recall: VITRUVIAS THERAPEUTICS INC: Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4
The FDA designated a Class I recall for Vitruvias Therapeutics' Thyroid Tablets, USP, 1/2 Grain (30 mg), each containing levothyroxine (T4) 19 mcg and liothyronine (T3) 4.5 mcg, due to the product being superpotent. The recalled lots were distributed as 100-count, prescription-only bottles under NDC 69680-166-00, manufactured in the USA by Vitruvias Therapeutics of Auburn, AL.
Most relevant for: Patients prescribed this combination levothyroxine/liothyronine thyroid tablet, including those using it for thyroid hormone replacement or as an augmentation agent in mood disorder treatment.
Read the original at FDA Drug Enforcement ReportsSummary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.
Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.
Specialties
More internal medicine updates
- Long-acting injectable noninferior to oral HIV therapy in adherence trialOct 15, 2026
- Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Ph-Positive ALL TrialOct 15, 2026
- Isoflurane sedation does not lower mortality in hypoxemic respiratory failureOct 14, 2026
- Trial finds higher mortality with intermittent vs continuous renal-replacement therapyOct 14, 2026
- No Overall Rise in Birth Defects With Early Benzodiazepine UseOct 13, 2026